1907. Clinical characteristics of invasive disease caused by a rare Group A Streptococcus subtype (emm26.3) — Alaska, 2016–2017
Session: Poster Abstract Session: Clinical: Bacteremia and Endocarditis
Saturday, October 7, 2017
Room: Poster Hall CD
  • Mosites GAS surveillance_clinical IDSA_10-3-17.pdf (436.9 kB)
  • Background: Clinical manifestations of Group A Streptococcus invasive disease (iGAS) can vary by molecular subtype (emm type). In Alaska, we complete emm typing and antimicrobial susceptibility testing for all isolates received by the statewide iGAS surveillance system. In February 2016, we identified a rare subtype, emm26.3, which had not been detected in Alaska previously. We compared the clinical characteristics of emm26.3 iGAS cases with those caused by other emm types.

    Methods: We defined a case as the isolation of GAS from a normally sterile body site in an Alaska resident from February 2016 to April 2017. We also included non-sterile site GAS isolates if the cases had a diagnosis of necrotizing fasciitis (NF) or streptococcal toxic shock syndrome (STSS). We requested medical records for all cases caused by emm26.3 and for cases of iGAS caused by non-emm26.3 types that were admitted to the same healthcare facility within three months of each emm26.3 case. We collected demographic, clinical, and laboratory data by using a standard chart abstraction form. We calculated P-values using logistic and linear regression.

    Results: We reviewed records for 53 cases of emm26.3 and 47 cases of other emm types (including emm1, 4, 11, 12, 49, 59, 81, and 91). Cases of emm26.3 had a mean age of 52 years; 37 (70%) were male and 41 (82%) were Alaska Native. Emm26.3 cases were more likely to have underlying alcohol use disorders than adult cases of other emm types (72% vs. 41%, p<0.01). Emm26.3 cases had significantly longer durations of hospitalization (median 11 days vs. 5 days, P=0.01) and were more likely to have GAS bacteremia (55% vs. 32%, p=0.02). The case fatality for emm26.3 was 9% (vs. 4% among non-emm26.3 cases, p=0.31). Severe disease diagnoses included sepsis (51% vs. 38%), NF (26% vs. 11%), and STSS (9% vs. 6%). Diagnosis with any of these severe diseases was higher among emm26.3 cases than non-emm26.3 types (P=0.02). Emm26.3 isolates were susceptible to ceftriaxone, penicillin, and erythromycin.

    Conclusion: Emm26.3 GAS is associated with severe invasive disease. Reasons for this could include characteristics of the bacterium or of the affected population. Further investigation into the virulence of the bacterium is warranted.

    Emily Mosites, PhD MPH1, Anna Frick, MPH2, Prabhu Gounder, MD MPH1, Louisa Castrodale, DVM2, Karen Rudolph, PhD1, K. Danielle Lecy, BSN1, Tammy Zulz, MPH1, Joseph Mclaughlin, MD2, Thomas Hennessy, MD, MPH1 and Michael Bruce, MD, MPH1, (1)Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, (2)Section of Epidemiology, Alaska Division of Public Health, Anchorage, AK


    E. Mosites, None

    A. Frick, None

    P. Gounder, None

    L. Castrodale, None

    K. Rudolph, None

    K. D. Lecy, None

    T. Zulz, None

    J. Mclaughlin, None

    T. Hennessy, None

    M. Bruce, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.